This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEB8506G_M.jpg
Regeneron Pharma announced earnings per share of $23.72 on revenue of $4.95B. Analysts polled by Investing.com anticipated EPS of $20.06 on revenue of $4.5B.
Regeneron Pharma shares are down 1.71% from the beginning of the year, still down 9.60% from its 52 week high of $686.62 set on September 3, 2021. They are outperforming the S&P 500 which is down 6.06% from the start of the year.
Regeneron Pharma’s report follows an earnings beat by UnitedHealth on January 19, who reported EPS of $4.48 on revenue of $73.74B, compared to forecasts EPS of $4.3 on revenue of $72.98B.
J&J had beat expectations on January 25 with fourth quarter EPS of $2.13 on revenue of $24.8B, compared to forecast for EPS of $2.12 on revenue of $25.28B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
